Citations

Clear

948 citation(s) found for "Li, Bryan".

Draft Genome Sequences of 24 Microbial Strains Assembled from Direct Sequencing from 4 Stool Samples
Jeraldo, Patricio , Hernandez, Alvaro G. , White, Bryan A. , O’Brien, Daniel R. , Ahlquist, David A. , Boardman, Lisa, Ahlquist, David, Boardman, Lisa, Chia, Nicholas , Jeraldo, Patricio R

Mayo Clinic

Genome Announcements | May 29, 2015 | Volume: 3 | Issue: 3 | Pages: No page available

10.1128/genomea.00526-15 | PMID 26021920 Get It

ABSTRACT The ability to assemble genomes from metagenomic sequencing avoids the need for culture and any associated culture biases. We assembled 24 essentially complete draft genomes from metagenomic pair-end and size-selected mate pair sequencing from 4 stool samples, 2 from subjects diagnosed with colorectal cancer and 2 from healthy controls.
Pain Management in Four‐Limb Amputation: A Case Report
Warner, Matthew A. , Moeschler, Susan M. , Hoelzer, Bryan C. , Warner, Nafisseh S. , Warner, Matthew A

Mayo Clinic

Pain Practice | May 26, 2015 | Volume: 15 | Issue: 7 | Pages: No page available

10.1111/papr.12307 | PMID 26011696 Get It

AbstractAcute pain following amputation can be challenging to treat due to multiple underlying mechanisms and variable clinical responses to treatment. Furthermore, poorly controlled preoperative pain is a risk factor for developing chronic pain. Evidence suggests that epidural analgesia and peripheral nerve blockade may decrease the severity of residual limb pain and the prevalence of phantom pain after lower extremity amputation. We present the perioperative analgesic management of a patient with gangrene of the bilateral upper and lower extremities as a result of septic shock and prolonged vasopressor administration who underwent four‐limb amputation in a single procedure. A multimodal analgesic regimen was utilized, including titration of preoperative opioid and neuropathic pain agents, perioperative intravenous, epidural and peripheral nerve catheter infusions, and postoperative oral medication titration. More than 8 months postoperatively, the patient has satisfactory pain control with no evidence for phantom limb pain. To our knowledge, there have been no publications to date concerning analgesic regimens in four‐limb amputation.
ACR Appropriateness Criteria ® Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis
Metastases:, Expert Panel on Radiation Oncology–Bone, Lo, Simon S. , Ryu, Samuel , Chang, Eric L. , Galanopoulos, Nicholas, Kim, Edward Y. , Kubicky, Charlotte Dai, Lee, Charles P., Rose, Peter S. , Sahgal, Arjun , Sloan, Andrew E. , Traughber, Bryan , Poznak, Catherine Van , Vassil, Andrew D. , Metastases:, Expert Panel on Radiation Oncology–Bone, Jones, Joshua , Teh, Bin Sing

Mayo Clinic

Journal of Palliative Medicine | May 14, 2015 | Volume: 18 | Issue: 7 | Pages: 573-584

10.1089/jpm.2015.28999.sml | PMID 25974663 Get It

Abstract Metastatic epidural spinal cord compression (MESCC) is an oncologic emergency and if left untreated, permanent paralysis will ensue. The treatment of MESCC is governed by disease, patient, and treatment factors. Patient's preferences and goals of care are to be weighed into the treatment plan. Ideally, a patient with MESCC is evaluated by an interdisciplinary team promptly to determine the urgency of the clinical scenario. Treatment recommendations must take into consideration the risk-benefit profiles of surgical intervention and radiotherapy for the particular individual's circumstance, including neurologic status, performance status, extent of epidural disease, stability of the spine, extra-spinal disease status, and life expectancy. In patients with high spinal instability neoplastic score (SINS) or retropulsion of bone fragments in the spinal canal, surgical intervention should be strongly considered. The rate of development of motor deficits from spinal cord compression may be a prognostic factor for ultimate functional outcome, and should be taken into account when a treatment recommendation is made. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Abstract 2540: Immune modulation by the TLR8 agonist VTX-2337; a comparison of the pharmacodynamic response in cancer patients and healthy volunteers
Dietsch, Greg, Northfelt, Donald W. , Ramanathan, Ramesh K., Cohen, Peter A. , Manjarrez, Kristi L., Newkirk, Mona, Bryan, James Kyle, Hershberg, Robert M.

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 2540-2540

10.1158/1538-7445.am2014-2540 Get It

Abstract Immunotherapy has proven to be a successful treatment approach for some cancer patients. One promising paradigm in immunotherapy is targeting pathogen-associated molecule pattern receptors (PAMPS) such as the toll-like receptors (TLRs) to activate the innate immune system and enhance the development of tumor-directed adaptive immune responses. However, an ongoing concern in the application of immunotherapeutics is the potential for the immune response in cancer patients to be less robust than in healthy individuals, due to the underlying advanced neoplastic disease or due to previous regimens of cytotoxic drugs. To address this concern in relation to the response to TLR8 stimulation, we compared the pharmacokinetic and pharmacodynamic (PK/PD) relationship defined in a phase 1 clinical trial of the selective small molecule TLR8 agonist VTX-2337 in oncology patients to the response in healthy volunteers. A phase 1 dose-escalation clinical trial (A101) in subjects with advanced solid tumors (n=33) demonstrated that plasma levels of multiple biomarkers of immune activation, including G-CSF, MCP-1, MIP1-β and TNFα, increased in a dose-dependent manner and correlated with increasing plasma levels of VTX-2337. The PK/PD relationship defined in the initial clinical trial was closely aligned with predictions from both in vitro assays and preclinical studies conducted in cynomolgus monkeys. A subsequent phase 1 trial (A105) was conducted as a single-center, open-label, two-period, randomized, crossover, phase 1 study in normal volunteers (n=10). The objective of this study was to compare the PK/PD profiles and local tolerance of two formulations of VTX-2337. In this study, the two preparations of VTX-2337 demonstrated comparable PK profiles and PD responses. At comparable dose levels, the PK profile and overall exposure (AUC) to VTX-2337 was similar for oncology patients and healthy volunteers. VTX-2337 induced the same repertoire of circulating cytokines and chemokines, indicative of TLR8 activation, in both populations. The magnitude of the mediator response in oncology patients was also highly comparable to the response in healthy volunteers that received a similar dose. This comparison demonstrates that the immune system of cancer patients with advanced disease remains highly responsive to TLR8 activation by VTX-2337. In summary, advanced neoplastic disease or a prior treatment history with cytotoxic agents that can negatively impact immune cell function did not appear to moderate the response to VTX-2337 based on the PK/PD relationship using predictive biomarkers. Citation Format: Greg Dietsch, Donald Northfelt, Ramesh Ramanathan, Peter Cohen, Kristi Manjarrez, Mona Newkirk, James Kyle Bryan, Robert Hershberg. Immune modulation by the TLR8 agonist VTX-2337; a comparison of the pharmacodynamic response in cancer patients and healthy volunteers. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2540. doi:10.1158/1538-7445.AM2014-2540
High functioning male with fragile X syndrome and fragile X‐associated tremor/ataxia syndrome
Basuta, Kirin, Schneider, Andrea , Gane, Louise W., Polussa, Jonathan, Woodruff, Bryan K. , Pretto, Dalyir, Hagerman, Randi J. , Tassone, Flora

Mayo Clinic

American Journal of Medical Genetics Part A | April 29, 2015 | Volume: 167 | Issue: 9 | Pages: 2154-2161

10.1002/ajmg.a.37125 | PMID 25920745 Get It

Fragile X syndrome (FXS) affects individuals with more than 200 CGG repeats (full mutation) in the fragile X mental retardation 1 (FMR1) gene. Those born with FXS experience cognitive and social impairments, developmental delays, and some features of autism spectrum disorders. Carriers of a premutation (55–200 CGG repeats) are generally not severely affected early in life; however, are at high risk of developing the late onset neurodegenerative disorder, Fragile X‐associated Tremor/Ataxia Syndrome (FXTAS), or Fragile X‐associated Primary Ovarian Insufficiency (FXPOI), and may have other medical conditions such as developmental delay, autism spectrum disorders, hypertension, anxiety, and immune‐mediated disorders. Here we present a case of a 58‐year‐old man with a borderline IQ, average memory skills, and executive function deficits. He met criteria for multiple psychiatric diagnoses and presented with tremor and ataxia, meeting criteria for FXTAS. Molecular testing unveiled a completely unmethylated FMR1 full mutation in peripheral blood mononucleated cells with elevated FMR1 mRNA and premutation alleles of different sizes in two other tissues (primary fibroblasts and sperm), indicating the presence of allele instability based on both inter‐ and intra‐tissue mosaicism. The observation of FXTAS in this case of a full mutation mosaic man suggests that the pathogenic mechanism underlying this disorder is not observed exclusively in premutation carriers as it was originally thought. The concomitant presence of features of FXS and late onset neurological deterioration with probable FXTAS likely result from a combined molecular pathology of elevated FMR1 mRNA levels, a molecular hallmark of FXTAS and low FMRP expression that leads to FXS. © 2015 Wiley Periodicals, Inc.
Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer
Sepucha, Karen , O’Neill, Anne, Motley, Christine, Swaby, Ramona F., Schneider, Bryan P. , Dang, Chau T. , Northfelt, Donald W. , Partridge, Ann H. , Miller, Kathy D. , Sledge, George W.

Mayo Clinic

JAMA Oncology | April 2, 2015 | Volume: 1 | Issue: 3 | Pages: 369

10.1001/jamaoncol.2015.0246 | PMID 26114161 Get It

APOE ε4 Genotype and the Risk for Subjective Cognitive Impairment in Elderly Persons
Woodruff, Bryan K. , Acosta, Jazmin I., Locke, Dona E.C. , Hentz, Joseph G. , Stonnington, Cynthia M. , Stokin, Gorazd B. , Nagle, Chelsea, Michel, Bernard François, Sambuchi, Nathalie, Caselli, Richard J. , Geda, Yonas E. , Krell-Roesch, Janina, Locke, Dona E, Michel, Bernard F, Krell‐Roesch, Janina , Geda, Yonas E , Locke, Dona E C , Stokin, Gorazd

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | March 24, 2015 | Volume: 27 | Issue: 4 | Pages: 322-325

10.1176/appi.neuropsych.14100268 | PMID 25803305 Get It

Voluntary and forced exercise differentially alters the gut microbiome in C57BL/6J mice
Allen, Jacob M. , Miller, Margret E. Berg , Whitlock, Keith G. , Nehra, Vandana, Gaskins, H. Rex , White, Bryan A. , Fryer, John Denis , Woods, Jeffrey A. , Pence, Brandt D, Whitlock, Keith, Fryer, John D., Pence, Brandt D.

Mayo Clinic

Journal of Applied Physiology | February 13, 2015 | Volume: 118 | Issue: 8 | Pages: 1059-1066

10.1152/japplphysiol.01077.2014 | PMID 25678701 Get It

We have previously shown that voluntary wheel running (VWR) attenuates, whereas forced treadmill running (FTR) exacerbates, intestinal inflammation and clinical outcomes in a mouse model of colitis. As the gut microbiome is implicated in colitis, we hypothesized that VWR and FTR would differentially affect the gut microbiome. Mice (9-10/treatment) were randomly assigned to VWR, FTR, or sedentary home cage control (SED) for 6 wk. VWR were given running wheel access, whereas FTR ran on a treadmill for 40 min/day at 8–12 m/min, 5% grade. Forty-eight hours after the last exercise session, DNA was isolated from the fecal pellets and cecal contents, and the conserved bacterial 16S rRNA gene was amplified and sequenced using the Illumina Miseq platform. Permutational multivariate analysis of variance based on weighted UniFrac distance matrix revealed different bacterial clusters between feces and cecal contents in all groups ( P < 0.01). Interestingly, the community structures of the three treatment groups clustered separately from each other in both gut regions ( P < 0.05). Contrary to our hypothesis, the α-diversity metric, Chao1, indicated that VWR led to reduced bacterial richness compared with FTR or SED ( P < 0.05). Taxonomic evaluation revealed that both VWR and FTR altered many individual bacterial taxa. Of particular interest, Turicibacter spp., which has been strongly associated with immune function and bowel disease, was significantly lower in VWR vs. SED/FTR. These data indicate that VWR and FTR differentially alter the intestinal microbiome of mice. These effects were observed in both the feces and cecum despite vastly different community structures between each intestinal region.
The Epidemiology and Health Care Burden of Tennis Elbow
Sanders, Thomas L. , Kremers, Hilal Maradit , Bryan, Andrew J., Ransom, Jeanine E. , Smith, Jay , Morrey, B.F. , Maradit Kremers, Hilal, Morrey, Bernard F, Ransom, Jeanine E, Smith, Jay, Morrey, B.F., Maradit Kremers, Hilal

Mayo Clinic

The American Journal of Sports Medicine | February 5, 2015 | Volume: 43 | Issue: 5 | Pages: 1066-1071

10.1177/0363546514568087 | PMID 25656546 Get It

Background: Lateral elbow tendinosis (epicondylitis) is a common condition both in primary care and specialty clinics. Purpose: To evaluate the natural history (ie, incidence, recurrence, and progression to surgery) of lateral elbow tendinosis in a large population. Study Design: Descriptive epidemiology study. Methods: The study population comprised a population-based incidence cohort of patients with new-onset lateral elbow tendinosis between January 1, 2000, and December 31, 2012. The medical records of a 10% random sample (n = 576) were reviewed to ascertain information on patient and disease characteristics, treatment modalities, recurrence, and progression to surgery. Age- and sex-specific incidence rates were calculated and adjusted to the 2010 US population. Results: The age- and sex-adjusted annual incidence of lateral elbow tendinosis decreased significantly over time from 4.5 per 1000 people in 2000 to 2.4 per 1000 in 2012 ( P < .001). The recurrence rate within 2 years was 8.5% and remained constant over time. The proportion of surgically treated cases within 2 years of diagnosis tripled over time, from 1.1% during the 2000-2002 time period to 3.2% after 2009 ( P < .00001). About 1 in 10 patients with persistent symptoms at 6 months required surgery. Conclusion: The decrease in incidence of lateral elbow tendinosis may represent changes in diagnosis patterns or a true decrease in disease incidence. Natural history data can be used to help guide patients and providers in determining the most appropriate course at a given time in the disease process. The study data suggest that patients without resolution after 6 months of onset may have a prolonged disease course and may need surgical intervention.
Cognitive profile of LRRK2‐related Parkinson's disease
Srivatsal, Sindhu, Leverenz, James B. , Uitti, Ryan J. , Trojanowski, John Q. , Quinn, Joseph F. , Chung, Kathryn A. , Peterson, Amie, Wood‐Siverio, Cathy, Goldman, Jennifer G. , Stebbins, Glenn T. , Bernard, Bryan, Ritz, Beate , Rausch, Rebecca , Revilla, Fredy J., Devoto, Johnna, Dawson, Ted M. , Albert, Marilyn S. , Mata, Ignácio F. , Hu, Shu‐Ching , Montine, Kathleen S. , Johnson, Catherine O., Montine, Thomas J. , Edwards, Karen L. , Cholerton, Brenna , Wszołek, Zbigniew K. , Dickson, Dennis W. , Weintraub, Daniel , Deerlin, Vivianna M. Van , Factor, Stewart Alan , Espay, Alberto J. , Rosenthal, Liana S. , Zhang, Jing , Zabetian, Cyrus P. , Goldman, Jennifer G , Leverenz, James B , Quinn, Joseph F

Mayo Clinic

Movement Disorders | February 4, 2015 | Volume: 30 | Issue: 5 | Pages: 728-733

10.1002/mds.26161 | PMID 25650144 Get It

AbstractBackgroundIncreasing evidence suggests that genetic factors play a role in the variability associated with cognitive performance in Parkinson's disease (PD). Mutations in the LRRK2 gene are the most common cause of monogenic PD; however, the cognitive profile of LRRK2‐related PD is not well‐characterized.MethodsA cohort of 1,447 PD patients enrolled in the PD Cognitive Genetics Consortium was screened for LRRK2 mutations and completed detailed cognitive testing. Associations between mutation carrier status and cognitive test scores were assessed using linear regression models.ResultsLRRK2 mutation carriers (n = 29) demonstrated better performance on the Mini Mental State Examination (P = 0.03) and the Letter‐Number Sequencing Test (P = 0.005). A smaller proportion of LRRK2 carriers were demented (P = 0.03).ConclusionsOur cross‐sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2‐related PD. Future longitudinal studies are needed to determine whether LRRK2 mutation carriers exhibit slower cognitive decline. © 2015 International Parkinson and Movement Disorder Society